How rhinovirus changes airway muscles and causes lasting breathing problems

Rhinovirus, airway smooth muscle, and mechanisms of irreversible airflow obstruction

NIH-funded research Rutgers Biomedical and Health Sciences · NIH-11310783

Researchers are looking at how common cold viruses change airway muscle cells and make bronchodilators less effective for people with asthma.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionRutgers Biomedical and Health Sciences NIH-funded
Lab location1 site (Newark, UNITED STATES)
Project IDNIH-11310783 on NIH RePORTER

What this research studies

This work uses human airway tissue and airway muscle cells in the lab to see how rhinovirus (a common cold virus) alters airway muscle tightening and relaxation. Investigators expose human airway epithelial cells and airway smooth muscle to rhinovirus C15 and measure calcium signals, Rho kinase activity, cAMP levels, and bronchodilator responses. They focus on inflammatory proteins such as TFF3 released by airway epithelium and test whether blocking TFF3 or its receptors can restore bronchodilator action in human lung slices and cell co-cultures. The goal is to understand why airflow obstruction can become harder to reverse after viral infections.

Who could benefit from this research

Good fit: People with asthma, especially those who have worsening symptoms after colds or recurrent rhinovirus-triggered exacerbations, or tissue donors providing airway samples, would be most relevant to this work.

Not a fit: People without airway disease or whose breathing problems are unrelated to viral triggers are unlikely to benefit directly from this project.

Why it matters

Potential benefit: If successful, this work could point to new ways to prevent or reverse virus-induced loss of bronchodilator effectiveness and reduce asthma exacerbations.

How similar studies have performed: Prior laboratory studies have shown rhinovirus can increase airway hyperreactivity and early data implicate TFF3 in reducing bronchodilator responses, but targeting TFF3 is a relatively new approach.

Where this research is happening

Newark, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.